Bruker is excited to participate in the ISBER 2022 Annual Meeting & Exhibits, scheduled to take place May 17-20, 2022 in Atlanta, Georgia, USA. During this event, the Bruker Team will moderate the "Emerging Technology, NMR Quality Control, Phenotyping, Digital Offering" roundtable and host the "Standardized NMR* Technology: A business opportunity for Biobanks" workshop during the in-person proceedings. The Bruker workshop will be held on Thursday, May 19th and will be available to registered attendees during the virtual session of the event.
As the world has evolved since the beginning of the COVID-19 pandemic, the need for enhanced quality control (QC) and phenotype metadata has never been more relevant. Nuclear magnetic resonance (NMR) is an emerging technology for biobanks and provides quality control (QC) and phenotype metadata for biofluids samples. In this roundtable, we hope to introduce a novel approach called “digital phenotyping,” explore the advantages and disadvantages, and to vet these concepts with experts in the biobanking community.
Bruker BioSpin has developed a new Clinical Research NMR platform that provides enhanced QC and phenotype analysis to increase the value of biobank samples. We also believe this standardized solution creates an opportunity for a new biobank offering in the form of a "digital phenotype" with several advantages. We would like to host a panel discussion to explore those concepts with experts in the field and engage in active dialog with the audience.
*Bruker NMR Instruments are for Research Use Only. Not for Use in Clinical Diagnostic Procedures.
Discover how a standardized NMR platform contributes to Biobank operations
Learn about the dedicated workflow for Biobanks
Learn how to add high investigative values to your biobank samples
Dr. Alexander Funke, Dresden Clinic and Lab diagnostic
Roland Leiminger, Bruker BioSpin
Glen Gregory, Bruker BioSpin